Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.

Lam AR, Bert NL, Ho SS, Shen YJ, Tang LF, Xiong GM, Croxford JL, Koo CX, Ishii KJ, Akira S, Raulet DH, Gasser S.

Cancer Res. 2014 Apr 15;74(8):2193-2203. doi: 10.1158/0008-5472.CAN-13-1703. Epub 2014 Mar 3.

2.

The DNA damage response induces antigen presenting cell-like functions in fibroblasts.

Tang ML, Khan MK, Croxford JL, Tan KW, Angeli V, Gasser S.

Eur J Immunol. 2014 Apr;44(4):1108-18. doi: 10.1002/eji.201343781. Epub 2014 Feb 16.

3.

ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells.

Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N, Phua CM, Chng WJ, Ng SB, Raulet DH, Gasser S.

Blood. 2013 Mar 28;121(13):2512-21. doi: 10.1182/blood-2012-08-449025. Epub 2013 Jan 24.

4.

Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling.

Martínez Gómez JM, Croxford JL, Yeo KP, Angeli V, Schwarz H, Gasser S.

J Neurosci. 2012 Dec 12;32(50):18246-52. doi: 10.1523/JNEUROSCI.2473-12.2012.

5.

CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.

Yeo YA, Martínez Gómez JM, Croxford JL, Gasser S, Ling EA, Schwarz H.

J Neuroinflammation. 2012 Jul 16;9:173. doi: 10.1186/1742-2094-9-173.

6.

Generation and characterization of a novel recombinant antibody against 15-ketocholestane isolated by phage-display.

Islam MO, Lim YT, Chan CE, Cazenave-Gassiot A, Croxford JL, Wenk MR, Macary PA, Hanson BJ.

Int J Mol Sci. 2012;13(4):4937-48. doi: 10.3390/ijms13044937. Epub 2012 Apr 19.

7.

Damage control: how HIV survives the editor APOBEC3G.

Croxford JL, Gasser S.

Nat Immunol. 2011 Sep 20;12(10):925-7. doi: 10.1038/ni.2115.

PMID:
21934670
8.

Suppression of experimental autoimmune encephalomyelitis by ghrelin.

Theil MM, Miyake S, Mizuno M, Tomi C, Croxford JL, Hosoda H, Theil J, von Hörsten S, Yokote H, Chiba A, Lin Y, Oki S, Akamizu T, Kangawa K, Yamamura T.

J Immunol. 2009 Aug 15;183(4):2859-66. doi: 10.4049/jimmunol.0803362. Epub 2009 Jul 20.

9.

Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies.

Croxford JL, Yamamura T.

Immunotherapy. 2009 May;1(3):403-23. doi: 10.2217/imt.09.7. Review.

PMID:
20635959
10.

NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora.

Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, Yamamura T.

Am J Pathol. 2008 Dec;173(6):1714-23. doi: 10.2353/ajpath.2008.080622. Epub 2008 Oct 30.

11.

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D.

J Neuroimmunol. 2008 Jan;193(1-2):120-9. Epub 2007 Nov 26.

PMID:
18037503
12.

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells.

Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN.

Nat Med. 2007 Apr;13(4):492-7. Epub 2007 Apr 1.

PMID:
17401376
13.
14.

Invariant V(alpha)19i T cells regulate autoimmune inflammation.

Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T.

Nat Immunol. 2006 Sep;7(9):987-94. Epub 2006 Jul 30.

PMID:
16878136
15.

Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression.

Croxford JL, Wang K, Miller SD, Engman DM, Tyler KM.

Cell Microbiol. 2005 Nov;7(11):1592-602.

PMID:
16207246
16.

Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?

Croxford JL, Yamamura T.

J Neuroimmunol. 2005 Sep;166(1-2):3-18. Review.

PMID:
16023222
18.

Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.

Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D.

J Neuroimmunol. 2005 Aug;165(1-2):41-52.

PMID:
15939483
19.

Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis.

Raijmakers R, Vogelzangs J, Croxford JL, Wesseling P, van Venrooij WJ, Pruijn GJ.

J Comp Neurol. 2005 Jun 6;486(3):243-53.

PMID:
15844172
20.
21.

Towards cannabis and cannabinoid treatment of multiple sclerosis.

Croxford JL, Miller SD.

Drugs Today (Barc). 2004 Aug;40(8):663-76. Review.

PMID:
15510238
22.

Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease.

Fuller KG, Olson JK, Howard LM, Croxford JL, Miller SD.

Methods Mol Med. 2004;102:339-61.

PMID:
15286394
23.

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D.

Brain. 2003 Oct;126(Pt 10):2191-202. Epub 2003 Jul 22.

PMID:
12876144
24.
25.
26.

Therapeutic potential of cannabinoids in CNS disease.

Croxford JL.

CNS Drugs. 2003;17(3):179-202. Review.

PMID:
12617697
27.
28.

A virus-induced molecular mimicry model of multiple sclerosis.

Olson JK, Croxford JL, Calenoff MA, Dal Canto MC, Miller SD.

J Clin Invest. 2001 Jul;108(2):311-8.

29.

Multiple pathways to induction of virus-induced autoimmune demyelination: lessons from Theiler's virus infection.

Miller SD, Olson JK, Croxford JL.

J Autoimmun. 2001 May;16(3):219-27. Review.

PMID:
11334486
31.

Immuno- and genetic therapy in autoimmune diseases.

Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford JL, Baker D, Podhajcer OL, Mageed RA.

Genes Immun. 2000 Jun;1(5):295-307. Review.

32.

Endocannabinoids control spasticity in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V.

FASEB J. 2001 Feb;15(2):300-2. Epub 2000 Dec 8.

PMID:
11156943
33.

Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L.

Nature. 2000 Mar 2;404(6773):84-7.

PMID:
10716447
34.

Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor.

Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D.

J Immunol. 2000 Mar 1;164(5):2776-81.

35.

Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis.

Croxford JL, O'Neill JK, Ali RR, Browne K, Byrnes AP, Dallman MJ, Wood MJ, Fedlmann M, Baker D.

Eur J Immunol. 1998 Dec;28(12):3904-16.

36.

Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.

Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y.

J Immunol. 1998 May 15;160(10):5181-7.

37.

Gene therapy for rheumatoid arthritis. Theoretical considerations.

Chernajovsky Y, Annenkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, Moyes SP, Croxford JL, Mageed RA, Podhajcer OL, Baker D.

Drugs Aging. 1998 Jan;12(1):29-41. Review.

PMID:
9467685
38.

Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice.

Croxford JL, O'Neill JK, Baker D.

J Neuroimmunol. 1997 Apr;74(1-2):205-11.

PMID:
9119975

Supplemental Content

Loading ...
Support Center